Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Vincristine and Dexamethasone in Relapsed/Refractory ALL
NCT00144963Phase 2Completed
- Sponsor
- Acrotech Biopharma Inc
- Start
- Jul 2002
- Primary completion
- Aug 2006
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vincristine sulfate liposome injection in acute lymphoblastic leukemia (ALL), sponsored by Acrotech Biopharma Inc. Primary endpoint: Maximum Tolerated Dose at 6 weeks. Started Jul 2002; status: completed.
02
Drugs
vincristine sulfate liposome injection
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00144963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00144963.